- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01476813
Randomized Cross Over Study to Assess Efficacy and Safety of BDP/FF and Glycopyrrolate
A Randomized, Double-blind, Active-controlled, Cross-over Study to Assess Efficacy and Safety of 3 Free Doses of Glycopyrrolate With Beclomethasone/Formoterol pMDI for the Treatment of COPD Patients
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Manchester, United Kingdom
- Medicines Evaluation Unit Ltd.
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- COPD over 40 years of age (30 to 60% post-bronchodilator FEV1 predictive value)
- Patients under Double
- Patients under triple therapy (for 1 Mo prior Screening)
Exclusion Criteria:
- Pregnant or lactating women
- Patients experiencing a COPD exacerbation requiring use of systemic steroids and/or antibiotics, hospitalization
- concommitant diseases impacting feasibility or safety
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: CROSSOVER
- Masking: QUADRUPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Glyco 25
BDP/FF (400/24 daily)+ Glyco 25µg daily
|
comparison of different dosages of drug
Other Names:
|
EXPERIMENTAL: Glyco 50
BDP/FF (400/24 daily)+ Glyco 50 µg daily
|
comparison of different dosages of drug
Other Names:
|
EXPERIMENTAL: Glyco 100
BDP/FF (400/24 daily)+ Glyco 100µg daily
|
comparison of different dosages of drug
Other Names:
|
ACTIVE_COMPARATOR: BDP/FF 400/24
|
comparison of different dosages of drug versus comparator
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Aera under curve FEV1 AUC 0-12h
Time Frame: day 1 and 7 of treatment period
|
day 1 and 7 of treatment period
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Dave Singh, MD, Clinical Pharmacology and Respiratory Medicine, Medicines Evaluation Unit Ltd, Manchester University
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Respiratory Tract Diseases
- Lung Diseases
- Lung Diseases, Obstructive
- Pulmonary Disease, Chronic Obstructive
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Muscarinic Antagonists
- Cholinergic Antagonists
- Cholinergic Agents
- Adjuvants, Anesthesia
- Glycopyrrolate
Other Study ID Numbers
- CCD-1106-PR-0066
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Chiesi commits to sharing with qualified scientific and medical Researchers, conducting legitimate research, Patient-level Data, Study-level Data, the Clinical Protocol and the full CSR, providing access to clinical trial information consistently with the principle of safeguarding commercially confidential information and patient privacy. Any shared Patient-level Data is anonymized to protect personally identifiable information.
Chiesi access criteria and complete process for clinical data sharing is available on the Chiesi Group website.
IPD Sharing Access Criteria
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pulmonary Disease, Chronic Obstructive
-
Spire, Inc.ResMedCompletedSevere Chronic Obstructive Pulmonary Disease | Moderate Chronic Obstructive Pulmonary DiseaseUnited States
-
Karaganda Medical UniversityCompletedChronic Obstructive Pulmonary Disease | Chronic Obstructive Pulmonary Disease Moderate | Chronic Obstructive Pulmonary Disease SevereKazakhstan
-
Randall DebattistaUniversity of Malta, Faculty of Health SciencesNot yet recruitingChronic Obstructive Pulmonary Disease Moderate | Acute Exacerbation of COPD | Chronic Obstructive Pulmonary Disease Severe
-
Cukurova UniversityCompletedAnesthesia | Chronic Obstructive Pulmonary Disease Moderate | Lungcancer | Chronic Obstructive Pulmonary Disease Severe | Chronic Obstructive Pulmonary Disease MildTurkey
-
National Taipei University of Nursing and Health...TerminatedChronic Pulmonary Disease | Chronic Obstructive Pulmonary Disease Exacerbation | Chronic Obstructive Pulmonary Disease With ExacerbationTaiwan
-
Taipei Medical UniversityUnknownChronic Obstructive Pulmonary Disease Severe | Chronic Obstructive Pulmonary Disease End StageTaiwan
-
Kırıkkale UniversityRecruitingCOPD (Chronic Obstructive Pulmonary Disease)Turkey
-
Hopital FochAir Liquide SARecruitingChronic Obstructive Pulmonary Disease SevereFrance
-
Fundación para la Investigación del Hospital Clínico...Not yet recruitingCOPD, Chronic Obstructive Pulmonary DiseaseSpain
-
Canandaigua VA Medical CenterRecruitingChronic Obstructive Pulmonary Disease ModerateUnited States
Clinical Trials on Glycopyrrolate
-
Sunovion Respiratory Development Inc.CompletedChronic Obstructive Pulmonary Disease
-
Journey Medical CorporationCompletedHyperhidrosisUnited States
-
Sunovion Respiratory Development Inc.CompletedChronic Obstructive Pulmonary Disease
-
NovartisCompletedChronic Obstructive Pulmonary Disease (COPD)France, Germany, Belgium, Spain, Turkey, Italy, Canada, Australia
-
Eunah Cho, MDCompletedCholecystitis, AcuteKorea, Republic of
-
University of MichiganNational Heart, Lung, and Blood Institute (NHLBI)CompletedCOPD (Chronic Obstructive Pulmonary Disease)United States
-
James J. Peters Veterans Affairs Medical CenterUnknownNeurogenic Bowel | Spinal Cord InjuryUnited States
-
Tanta UniversityUnknown
-
ShionogiCompletedCerebral Palsy | Sialorrhea | Mental Retardation | Neurological ConditionsUnited States
-
Novartis PharmaceuticalsCompletedChronic Obstructive Pulmonary Disease (COPD)Germany, Belgium, Netherlands, Canada, United States